Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 2/20 | 0.50 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | CTSK | P43235 | 4/20 | 0.47 |
| ▸ | SLC6A9 | P48067 | 13/20 | 0.46 |
| ▸ | CTSV | O60911 | 1/20 | 0.41 |
| ▸ | CTSL | P07711 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2096597 | 0.83 | CTSS (0.47) | P2RX7CTSSCTSKSLC6A9CTSV | |
| SCHEMBL10234211 | 0.82 | SLC6A9 (0.66) | P2RX7CTSSCTSKSLC6A9 | |
| SCHEMBL2054784 | 0.81 | SLC6A9 (0.51) | P2RX7CTSSCTSKSLC6A9 | |
| SCHEMBL2054782 | 0.81 | SLC6A9 (0.53) | P2RX7CTSSCTSKSLC6A9 | |
| SCHEMBL2054769 | 0.81 | SLC6A9 (0.49) | P2RX7CTSSCTSKSLC6A9 | |
| SCHEMBL2054765 | 0.80 | SLC6A9 (0.48) | P2RX7CTSSCTSKSLC6A9 | |
| SCHEMBL2056353 | 0.80 | SLC6A9 (0.70) | P2RX7CTSSCTSKSLC6A9 | |
| SCHEMBL10233695 | 0.80 | SLC6A9 (0.70) | P2RX7CTSSCTSKSLC6A9 | |
| SCHEMBL2056431 | 0.80 | SLC6A9 (0.70) | P2RX7CTSSCTSKSLC6A9 | |
| SCHEMBL2056422 | 0.80 | SLC6A9 (0.70) | P2RX7CTSSCTSKSLC6A9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1899294-B1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME (GB) | 2015-03-18 | — | — | EP | disclosed |
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-8163956-B2 | Inhibitors of GLYT1 transporters | MERCK SHARP & DOHME CORP. (US) | 2012-04-24 | — | — | US | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| US-20090286765-A1 | Therapeutic Agents | MERCK SHARP & DOHME (UK) LIMITED (GB) | 2009-11-19 | — | — | US | disclosed |
| WO-2006134341-A1 | THERAPEUTIC AGENTS | MERCK SHARP & DOHME LIMITED (GB) | 2006-12-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286765-A1 | Therapeutic Agents | GRIA1, GRIN1, GLRA1 | P2RX7 3458/4885CTSS 2889/4885CTSK 3103/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.